Bcl-W

BCL-W, an anti-apoptotic member of the BCL-2 family, promotes cell survival by inhibiting mitochondrial-mediated apoptosis^[1][2][3]. Structurally, BCL-W contains eight α-helices, with a C-terminal α8 helix that modulates interactions with BH3-only pro-apoptotic proteins, distinguishing it from BCL-2 and BCL-xL^[1][4]. Mechanistically, BCL-W regulates cell fate by integrating signals from PI3K/Akt and β-catenin pathways, enhancing invasion, mesenchymal transitions, and survival in cancer models including gastric cancer and glioblastoma^[5][6][3]. In disease contexts, BCL-W supports B-cell lymphoma cell survival, affects antiestrogen responsiveness in breast cancer, and protects neurons in epilepsy and Alzheimer’s disease models^{[2][7][8][9][3]}. Compared with related isoforms, BCL-W shows tissue-specific functions, such as essential roles in spermatogenesis and axonal maintenance in sensory neurons, whereas it is dispensable for survival in other cell types^{[10][11][12][3]}. Pharmacologic and genetic studies indicate that BCL-W modulates sensitivity to BH3-mimetics and microtubule inhibitors, influencing apoptosis thresholds in cancer cells^[13][14][3]. Despite its structural similarity to BCL-2 and BCL-xL, the unique C-terminal helix and transcriptional regulation by microRNAs, including miR-122, confer distinct regulatory features and therapeutic relevance^[1][15][3]. Current research explores dual BCL-W/BCL-xL degraders and selective inhibitors as potential anti-cancer strategies^[16][3].